#Japan #Nagoya #Okayama University #Nagoya University #Varte

Announcing Approval of Absorbable Bone Regeneration Material 'Varte'

The National University Corporation, Nagoya University, and Okayama University, in collaboration with Menicon Co., Ltd., have announced significant advancements in medical technology with the approval of their absorbable bone regeneration material, 'Varte', as a medical device in Japan. This achievement, disclosed on April 7, 2026, signifies a leap forward in regenerative medicine, particularly in orthopedics.

Background and Collaboration

The joint research leading to the development of 'Varte' integrates expertise from various departments. The Graduate School of Medicine at Nagoya University, focusing on Orthopedic Surgery, collaborated closely with the Graduate School of Medicine and Dentistry at Okayama University, particularly the field of System Physiology, also in conjunction with Menicon Co., Ltd. This multi-faceted partnership underscores the importance of interdisciplinary collaboration in achieving innovative healthcare solutions.

Approval Details

On February 13, 2026, 'Varte' received its medical device approval number 30800BZX00042000, classified as Class IV. The material is intended to aid in bone regeneration by combining it with autologous bone for implantation in areas lacking bone. This solution is particularly crucial for applications where the device does not bear load and is not directly involved in the initial bone stabilization of implants.

Expected Impact on Healthcare

The self-assembling peptide gel technology utilized in 'Varte' is anticipated to contribute significantly to the field of bone healing. By providing a scaffold that supports the body's natural healing processes, it is expected that 'Varte' will enhance patient outcomes in orthopedic surgery, reducing the time and complications associated with bone regeneration.

In light of Japan’s aging population, where bone-related health issues are increasingly prevalent, the introduction of such innovative materials offers hope for improved health care services. Moreover, as the global medical community keeps pushing for advancements in regenerative medicine, 'Varte' positions Japan at the forefront of these efforts, showcasing homegrown innovation inmedical technology.

Future Directions

The collaborative research teams from Okayama and Nagoya Universities are committed to furthering their research on absorbable materials and expanding their potential applications in medical devices. This path-forward shows a promising horizon for enhancing surgical techniques and patient recovery through innovative materials.

As the University continues to promote the synergy between education, research, and community impact, the approval of 'Varte' is a testament to the commitment towards contributing positively to public health and advancing scientific learning in Japan.

Contact Information for Inquiries

For further information about this development, inquiries can be directed to:

• - Nagoya University: Professor Shiro Imagama, Graduate School of Medicine, Orthopedic Surgery. Phone: 052-744-2040
• - Okayama University: Professor Keiji Naruse, Graduate School of Medicine and Dentistry. Phone: 086-235-7112
• - Menicon Co., Ltd.: Public Relations Department. Phone: 052-935-1187

Through continued collaboration and innovation, the stakeholders involved in the development of 'Varte' look forward to paving new paths in the field of regenerative medicine. The future of bone healing appears brighter with 'Varte' now on the market, fostering hope and healing for countless patients in need.